Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients

Journal of Allergy and Clinical Immunology

Volumn 106, Issue 1 I, 2000, Pages 101-109

  Nopp, Anna ^a   Halldén, Gunilla ^a   Lundahl, Joachim ^a   Johansson, Eva ^a   Vrtala, Susanne ^b,c   Valenta, Rudolf ^b,c   Grönneberg, Reidar ^a   Van Hage Hamsten, Marianne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

CD69; Eosinophil cationic protein; Eosinophils; Hyopallergenic derivatives; RBet v 1; Recombinant birch pollen allergens; Skin blister chambers

Indexed keywords

ALLERGEN; CHEMOKINE; CYTOKINE; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE; POLLEN ANTIGEN;

ADULT; ALLERGENICITY; ARTICLE; BULLOUS SKIN DISEASE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MALE; POLLEN ALLERGY; PRIORITY JOURNAL; TH2 CELL;

EID: 0033942152     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.106924     Document Type: Article

References (37)

1. Jarolim E, Rumpold H, Endler AT, Ebner H, Breitenbach M, Schneider, et al. IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy 1989;44:385-95.
2. Elfman L, Svensson M, Lidholm J, Pauli G, Valenta R. Different profiles in specific IgE to rBet v 1 and rBet v 2 in patients allergic to birch pollen from six countries. Int Arch Allergy Immunol 1997;113:249-51.
3. Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, Rumpold H, et al. The gene coding for the major birch pollen allergen, Bet v 1, is highly homologous to a pea diseases resistance response gene. EMBO J 1989;8:1935-8.
4. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al. Conversion of the major birch pollen allergen, Bet v 1, into two non-anaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:1673-81.
5. Vrtala S, Hirtenlehner K, Susani M, Hufnagl P, Binder BR, Vangelista L, et al. Genetic engineering of recombinant hypoallergenic oligomers of the major pollen allergen, Bet v 1: candidates for specific immunotherapy. Int Arch Allergy Immunol 1999;118:218-9.
6. van Hage-Hamsten M, Kronqvist M, Zetterström O, Johansson E, Niederberger V, Vrtala S, et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and rBet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999;104:969-72.
7. Pauli G, Purohit A, Oster J-P, De Blay F, Vrtala S, Niederberger V, et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wildtype by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy. In press.
8. Wardlaw AJ. Eosinophils in the 1990s: new perspectives on their role in health and disease. Postgrad Med J 1994;70:536-52.
9. De Monchy JG, Kauffman HF, Venge P, Koeter GH, Jonsen HM, Sluiter HJ, et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985;131:373-6.
10. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemival analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993;147:1126-31.
11. Synek M, Beasley R, Frew AJ, Goulding D, Holloway L, Lampe FC, et al. Cellular infiltration of the airways of varying severity. Am J Respir Crit Care Med 1999;154:224-30.
12. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology 1993;80:281-6.
13. Nishikawa K, Morii T, Ako H, Hamada K, Saito S, Narita N. In vivo expression on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. J Allergy Clin Immunol 1992;90:169-74.
14. Raud J, Halldén G, Roquet A, van Hage-Hamsten M, Alkner U, Hed J, et al. Anti-IgE-induced accumulation of leukocytes, mediators, and albumin in skin chamber fluid from healthy and atopic subjects. J Allergy Clin Immunol 1996;97:1151-63.
15. Fernvik E, Grönneberg R, Lundahl J, Raud J, Zetterström O, van Hage-Hamsten M, et al. Characterisation of eosinophils and detection of eotaxin in skin chamber fluid after challenge with relevant allergen in patients with mild asthma. Clin Exp Allergy 1999;29:1515-25.
16. Hoffmann-Sommergruber K, Susani M, Ferreira F, Jertschin P, Ahorn H, Steiner R, et al. High-level expression and purification of the major birch pollen allergen, Bet v 1. Protein Expr Purif 1997;9:33-9.
17. Halldén G, Andersson U, Hed J, Johansson SGO. A new membrane permeabilization method for the detection of intracellular antigens by flow cytometry. J Immunol Meth 1989;124:103-9.
18. Hed J, Halldén G. Counts of activated blood eosinophils for monitoring asthma. Allergy 1993;48:1787-93.
19. Fernvik E, Halldén G, Lundahl J, Raud J, Alkner U, van Hage-Hamsten M, et al. Allergen induced accumulation of eosinophils and lymphocytes in skin chambers is associated with increased levels of IL-4 and sVCAM-1. Allergy 1999;54:455-63.
20. Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissue. Am J Respir Cell Mol Biol 1999;21:291-5.
21. Tai PC, Spry CJF, Peterson C, Venge P, Olsson I. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature 1984;309:182-4.
22. Nakajima H, Loegering DA, Kita H, Kephart GM, Gleich GJ. Reactivity of monoclanal antibodies EG1 and EG2 with eosinophils and their granule proteins. J Leukoc Biol 1999;66:447-54.
23. Skedinger M, Halldén G, Lundahl J, Hed J, Zetterström O. Eosinophil activity reflects clinical status in patients with asthma before and during a predisolone course. Ann Allergy Asthma Immunol 1995;75:250-5.
24. Fernvik E, Grönneberg R, Lundahl J, Hed J, Andersson O, Johansson SGO, et al. The degree of natural allergen exposure modifies eosinophil activity markers in the circulation of patients with mild asthma. Allergy 1996;51:697-705.
25. Halldén G, Nopp A, Ihre E, Peterson C, Lundahl J. Conditions in blood sampling conditions that extend the ex vivo stability of eosinophil activity markers in peripheral blood from allergic patients and healthy controls. Ann Allergy Asthma Immunol 1999;83:413-21.
26. Fernvik E, Lundahl J, Halldén G. The impact of eotaxin-and IL5-induced adhesion and transmigration of eosinophil activity markers. Inflammation 2000;1:73-87.
27. Nopp A, Lundahl J, Halldén G. Quantitative, rather than qualitative, differences in CD69 upregulation in human blood eosinophils upon activation with selected stimuli. Allergy 2000;55:148-56.
28. Fernvik E, Lundahl J, Magnusson CGM, Halldén G. The effect of in vitro activation and platelet interaction on the CD9 distribution and adhesion properties of human eosinophils. Inflamm Res 1999;48:28-35.
29. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/machrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991;174:745-8.
30. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999;54:825-57.
31. Moqbel R, Ying S, Barkans J, Newman TM, Kimmitt P, Wakelin M, et al. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995;155:4939-47.
32. Vowels BR, Rook AH, Cassin M, Zweiman B. Expression of interleukin-4 and interleukin-5 mRNA in developing cutaneous late phase reactions. J Allergy Clin Immunol 1995;96:92-6.
33. Zweiman B, Kaplan AP, Tong L, Moskovitz BS. Cytokine levels and inflammatory responses in developing late-phase reactions in the skin. J Allergy Clin Immunol 1997;100:104-9.
34. Irani AM, Huang C, Xia HZ, Kepley C, Nafie A, Fouda ED, et al. Immunohistochemical detection of human basophils in late-phase skin reactions. J Allergy Clin Immunol 1998;101:354-62.
35. Charlesworth EN, Kagney-Sobotka A, Schleimer RP, Norman PS, Lichtenstein LM. Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol 1991;146:671-6.
36. Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG, et al. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 34-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999;163:3976-84.
37. Yamada N, Wakugawa M, Kuwata S, Yoshida T, Nakagawa H. Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects. J Allergy Clin Immunol 1995;96:1069-75.